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Focal cortical dysplasiaRasmussen's encephalitis is a rare syndrome characterized by intractable seizures, often associatedwith epilepsia
partialis continua and symptoms of progressive hemispheric dysfunction. Seizures are usually the hallmark of
presentation, but antiepileptic drug treatment fails in most patients and is ineffective against epilepsia partialis
continua, which often requires surgical intervention. Co-occurrence of focal cortical dysplasia has only rarely
been described and may have implications regarding pathophysiology and management. We describe a rare
case of dual pathology of Rasmussen's encephalitis presenting as a focal cortical dysplasia (FCD) and discuss
the literature on this topic.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Rasmussen's encephalitis (RE) is a rare but severe immune-mediated
brain disorder leading to unilateral hemispheric atrophy, associated
progressive neurological dysfunction with intellectual decline, and
intractable seizures [1–4]. It is a well-established cause of pharmacologi-
cally intractable epilepsy. Antiepileptic drug treatment fails in most
patients and is ineffective against epilepsia partialis continua (EPC),
which often requires surgical intervention [4]. Given the presence of
autoantibodies in many cases, particularly GluR3 autoantibodies, a
variety of immunotherapy treatments have been attempted with varied
success [5–7].
Pathological features resemble a viral encephalitis. A viral cause of
RE was suggested by Rasmussen et al. in 1958 [8]; however, reliable
identiﬁcation of an offending infectious agent has not been successful.
Proposed etiologies have included defects in the humoral and innate
immune systems. Microscopic analysis usually reveals inﬂammatory
hallmarks of the disease, consisting of widespread perivascular T-cell
inﬁltration and microglial nodule formation with neuronal cell
death and cortical atrophy characteristic of advanced disease stage
[4,9].
Co-occurrence of the destructive pathology of RE with dysplastic
features in cortical architecture has only rarely been described but
may have implications regarding pathophysiology and management
[10–15]. Indeed, the role of other principal brain lesions in RE remainson of Epilepsy, Fegan 9, Boston
A.
. This is an open access article undercontroversial [16]. Therefore, we describe a rare case of dual pathology
of RE presenting as a focal cortical dysplasia (FCD) and discuss the liter-
ature on this topic.2. Case report
A previously healthy, 10-year-old right-handed girl with prior
normal development presented at 8.5 years with twitching of the
right side of her body initially involving the face and, later, arm, and
leg. The twitching became essentially continuous during both wakeful-
ness and sleep and evolved into epilepsia partialis continua (EPC). Elec-
troencephalogram (EEG) showed frequent left-side spikes, but the
initial MRI was normal and did not show any hemiatrophy.
One month postseizure onset, she developed recurrent fever, rash,
lymphadenopathy, andmouth ulcers. She underwent an extensive infec-
tious/inﬂammatory work-up which was signiﬁcant for positive cerebral
spinal ﬂuid (CSF) oligoclonal bands. A lymph node biopsywas consistent
with Kikuchi–Fujimoto disease, an idiopathic disorder characterized by
fever and lymphadenopathy that may have an autoimmune basis and a
possible association with systemic lupus erythematosus. However,
investigations for lupus were unrevealing. The patient underwent im-
munotherapy involving steroids and immunoglobulin but without any
clinical improvement.
The patient's EPC remained refractory to multiple anticonvulsant
medications and a course of transcranial magnetic stimulation (TMS).
She developed signiﬁcant functional impairment initially affecting
speech articulation and later developed an expressive aphasia withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Coronal T1 image showing blurring of the gray–white matter interface at the left
precentral gyrus suspicious for focal cortical dysplasia.
Fig. 2. Leptomeningeal and cortical lymphocytes.
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evaluation showed cognitive decline. There was no hemiparesis.
Follow-upMRI 2 months postseizure onset demonstrated blurringof
the gray–white junction in the left precentral gyrus and was concerning
for a cortical dysplasia (Fig. 1). However, differential diagnosis still
included a Rasmussen's encephalitis or a nonspeciﬁc autoimmune
process. Given the persistent pharmacologically refractory focal
seizures, the patient underwent a surgical evaluation. Electroencephalo-
gram showed multiregional left hemispheric spikes and slowing.
Positron emission tomography (FDG-PET) showed an area of hypo-
metabolism in the left precentral gyrus, but therewas no focal increased
radiotracer uptake with ictal single-photon emission computed tomog-
raphy. Magnetoencephalography showed a spike dipole cluster at the
left precentral gyrus.
Motor mapping performed with TMS and functional MRI (fMRI)
showed typical contralateral motor innervation butwas directly related
to the left precentral gyrus of concern. Language fMRI activation
patterns recorded during passive language tasks were consistent with
bilateral language activation in temporoparietal regions slightly favor-
ing the left hemisphere and typical left-lateralizated frontal lobe
processing.
Given the concordant data for a left precentral lesion, the patient
underwent invasive EEG monitoring to better localize the seizure
onset zone. Grids and strips were placed over the left hemisphere con-
vexity, and a wedge biopsy of the cortex was taken. This conﬁrmed
that the seizure onset zone overlapped the eloquent left hemisphere
primary motor cortex for the contralateral hand, throat, and jaw and
the left sensory cortex for the face.
Biopsy subsequently showed a mild to moderate T lymphocyte pre-
dominant inﬂammatory inﬁltrate in the cortex and white matter with
microglial nodules, which was consistent with Rasmussen's encephali-
tis, but the overall pathological picture wasmild (Figs. 2 and 3). In addi-
tion, rare dysplastic neurons were seen, suggesting a possible cortical
dysplasia (Fig. 3d). Balloon cells were not identiﬁed. There was reactive
gliosis, without vasculitis or viral inclusions.
In an attempt to avoid any deﬁcits, the patient underwent a partial
resection in the left frontal lobe, avoiding areas which mapped to
hand motor function and language, and multiple subpial transections
in the area of handmotor functionwere performed. Tissue taken during
this surgery was similar to the one taken from the previous biopsy.
Following surgery, the patient started a monthly course of intrave-
nous immunoglobulin (IVIG). At 3 months postop, her family felt that
she had started to show some improvement, with her right hand be-
coming more functional and with decreased hand twitching, especially
during sleep.3. Discussion
Rasmussen's encephalitis is a rare syndrome characterized by intrac-
table seizures, often associated with EPC and symptoms of progressive
hemispheric dysfunction [1–4]. The typical features of RE are onset in
childhood with a peak of incidence at the age of 6 years [3] and devel-
opment of slowly progressive, neurological deterioration including
hemiparesis, cognitive impairment, aphasia when the dominant hemi-
sphere is involved, and imaging evidence of progressive, usually unilat-
eral, cerebral atrophy. Seizures are the most common initial symptom.
The pathogenesis of RE is still largely unclear. A causative pathogenic
viral agent has so far not been identiﬁed. Evidence supporting GluR3
autoantibody-induced injury is conﬂicting, and there are cases in
which such autoantibodies do not appear to exist [4]. Rasmussen's
encephalitis is now believed to be an ongoing and progressive
immune-mediated process which induces apoptotic neuronal cell
death and involves the neuroglial and lymphocytic response, leading
to progressive deterioration of a single hemisphere [4,9]. These ﬁndings
suggested a potential beneﬁt of antiinﬂammatory and immune-
suppressive therapy in patients with RE in order to attenuate seizures
as well as progressive neurological deﬁcits. Indeed, antiepileptic drug
treatment fails in most patients and is ineffective against EPC. On the
other hand, immunomodulation, plasmapheresis, and antiviral treat-
ment approacheswere reported to be beneﬁcial to only a limited extent,
slowing cognitive decline but having no effect on established EPC
[5–7,17]. Indeed, our case had signiﬁcant evidence for immune activa-
tion with oligoclonal bands present in the CSF and lymph node biopsy
showing features of Kikuchi–Fujimoto disease, justifying immunotherapy
in this patient prior to establishing the diagnosis of RE.
Dual pathologymay be noted in 10% of patients and varies from low-
grade tumor, cortical dysplasia, tuberous sclerosis, mesial temporal
sclerosis, vascular abnormalities, or old ischemic lesions [16]. The
earliest MRI changes include ﬁrstly cortical swelling, with a hyperin-
tense T2/FLAIR signal (Stage 1). Later, normal volume and hyperintense
signalwere seen (Stage 2), followed by atrophy and hyperintense signal
(Stage 3) and then progressive atrophywith normal signal (Stage 4) [2].
Atrophy and signal change are most prominent in the perisylvian
region. In addition, other ﬁndings include atrophy of the ipsilateral
head of the caudate nucleus in the majority of cases [18,19]. True bilat-
eral RE is rare [20,21]. In our case, the persistentMRI ﬁnding of blurring
of the gray–white junction in the left precentral gyrus was concerning
for a cortical dysplasia. This was in the absence of other neuroimaging
changes typical for RE. In addition, FDG-PET showed an area of
hypometabolism in the left precentral gyrus, giving further evidence
towards a focal lesion in our case.
Fig. 3. a. CD45: lymphocytes, slightly more numerous than those seen on H&E. b. CD3: virtually all T-cells (no B-cells). c. GFAP: reactive gliosis. d. Rare SMI31 positive neurons of unclear
signiﬁcance.
88 D.J. O'Rourke et al. / Epilepsy & Behavior Case Reports 2 (2014) 86–89All cases of RE and FCD involve children with a seizure onset in the
ﬁrst decade of life [10–15]. In all cases, theperioperative imaging studies
did not reveal dual pathology, although FCD was considered in some.
This current report is different in that a lesion concerning for FCD was
identiﬁed on neuroimaging, but there was no evidence of RE. Instead,
the combined clinical picture of EPC along with a T-cell-dominated
encephalitis with activated microglia fulﬁlled the diagnostic criteria
for RE in our case [4].
According to the new ILAE classiﬁcation systemof FCD [22], FCD type
IIId is associated with lesions acquired during early life, i.e., traumatic
brain injury, glial scarring after prenatal or perinatal ischemic injury or
bleeding, and inﬂammatory or infectious diseases. Wang et al. identiﬁed
four patients with RE and FCD type IIId [15]. This ﬁnding further supports
a role for the concept of acquired and postmigrational pathomechanisms
in the etiology of FCDs [23].
Little has been offered to explain the presence of dual pathology. One
hypothesis suggests that the focal cortical dysplasiamay cause alterations
in the blood–brain barrier, allowing circulating antibodies, antigens, and
inﬂammatory cells access to the brain and promoting development
of Rasmussen's encephalitis [13]. Another explanation could be that
neurogenesis may be induced by seizures produced by Rasmussen's
encephalitis resulting in a cortical dysplasia in the affected area
[13].
Results of focal resections in patients with RE are disappointing.
Hemispherectomy, a surgical procedure for total or partial removal of
a cerebral hemisphere, is considered a highly effective therapy to
achieve seizure control in RE [4]. Either anatomical or functional hemi-
spherectomy has been proposed [24,25]. Anatomical hemispherectomy
has largely been abandoned because of postoperative mortality caused
by hydrocephalus, hemosiderosis, and trivial head traumas [26]. The
goal of hemispherectomy is to achieve complete seizure control,
promote neurodevelopmental progress in the unaffected contralateral
hemisphere, and avoid seizure-related comorbidities. In our case,
the mapped seizure onset zone overlapped the eloquent motor and
sensory cortex. As the family was unwilling to proceed with a hemi-
spherectomy but was keen for more limited surgical intervention,
we opted to perform a partial cortical resection and multiple subpial transections in order to limit any motor deﬁcits. While this sur-
gery appears to have reduced the severity of EPC three months
postoperation, it is likely that she will require a more deﬁnitive hemi-
spherectomy in the future.Conﬂict of interest statement
The authors have no conﬂict of interests in the publication of this
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